RRMS
MCID: RLP002
MIFTS: 48

Relapsing-Remitting Multiple Sclerosis (RRMS) malady

Summaries for Relapsing-Remitting Multiple Sclerosis

Sources:
8Disease Ontology, 33MalaCards
See all sources

Fully expand this MalaCard

Export this MalaCard
Disease Ontology:8 A multiple sclerosis that is characterized by relapse (attacks of symptom flare-ups) followed by remission (periods of recovery). symptoms may vary from mild to severe, and relapses and remissions may last for days or months. more than 80 percent of people who have ms begin with relapsing-remitting cycles.

MalaCards: Relapsing-Remitting Multiple Sclerosis, also known as multiple sclerosis, relapsing-remitting, is related to progressive relapsing multiple sclerosis and multiple sclerosis 1. An important gene associated with Relapsing-Remitting Multiple Sclerosis is MIR17 (microRNA 17), and among its related pathways are Classical antibody-mediated complement activation and Immune response Fc epsilon RI pathway. The drugs glatiramer acetate and glatiramer and the compounds quinolinic acid and pge2 have been mentioned in the context of this disorder. Affiliated tissues include spinal cord, brain and lung.

Aliases & Classifications for Relapsing-Remitting Multiple Sclerosis

Sources:
8Disease Ontology, 45Novoseek, 61UMLS, 35MeSH, 57SNOMED-CT
See all sources

Aliases & Descriptions:

relapsing-remitting multiple sclerosis 8
multiple sclerosis, relapsing-remitting 61
multiple sclerosis relapsing-remitting 45
relapsing-remitting ms 8
rrms 8


External Ids:

Disease Ontology8 DOID:2378
SNOMED-CT57 426373005
MeSH35 D020529

Related Diseases for Relapsing-Remitting Multiple Sclerosis

Sources:
17GeneCards, 18GeneDecks
See all sources

Diseases related to Relapsing-Remitting Multiple Sclerosis via text searches within MalaCards or GeneCards/GeneDecks gene sharing:

(show top 50)    (show all 70)
idRelated DiseaseScoreTop Affiliating Genes
1progressive relapsing multiple sclerosis10.7
2multiple sclerosis 110.7
3secondary progressive multiple sclerosis10.5
4pediatric multiple sclerosis10.5
5multiple sclerosis 210.5
6neuromyelitis optica10.4
7primary progressive multiple sclerosis10.4
8wallerian degeneration10.4
9spasticity10.4
10multiple sclerosis 310.4
11polyarteritis nodosa10.3
12mu chain disease10.3
13acute disseminated encephalomyelitis10.3
14progressive multifocal leukoencephalopathy10.3
15brain disease10.3
16thrombocytopenia10.3
17cerebellar degeneration10.3
18idiopathic neutropenia10.3
19mycobacterium kansasii10.3
20paraneoplastic cerebellar degeneration10.3
21cerebral atrophy10.3
22headache10.3
23memory impairment10.3
24hematopoietic stem cell transplantation10.3
25diffuse gastric cancer10.0
26hepatitis10.0IFNB1
27acute leukemia10.0HLA-G
28hepatitis c10.0IFNB1
29dermatitis10.0NTF3, FOXP3, CXCL11
30herpes simplex10.0IFNB1, NTF3
31ovarian cancer10.0CCR7, IFNB1, HLA-G
32breast cancer10.0IFNB1, CCR7, HLA-G
33inflammatory bowel disease10.0FOXP3
34optic neuritis10.0IFNB1
35encephalomyelitis10.0IFNB1, NTF3, IL23A, CCR7
36myeloma10.0KLRK1, HLA-G
37pneumonia10.0AOC3, SAA4
38osteosarcoma10.0IFNB1
39dermatomyositis10.0CCR7
40diabetes mellitus10.0FOXP3, AOC3
41colorectal cancer10.0CCR7, HLA-G, KLRK1
42adenocarcinoma10.0KLRK1, IFNB1, HLA-G, NTF3
43arthritis10.0SAA4, FOXP3, IL23A, AOC3, CCR7
44skin cancer10.0MMP19
45influenza10.0CCR7, IFNB1
46ischemia10.0PTAFR, NTF4, NTF3, HCRT
47hepatocellular carcinoma10.0CCR7, KLRK1, IFNB1, FOXP3, AOC3
48stomach cancer10.0KLRK1, CCR7, IFNB1, PTAFR
49cervical cancer10.0HLA-G
50psoriasis10.0PTAFR, AOC3, MMP19, IL23A, HLA-G, CCR7

Graphical network of the top 20 diseases related to Relapsing-Remitting Multiple Sclerosis:



Diseases related to relapsing-remitting multiple sclerosis

Clinical Features for Relapsing-Remitting Multiple Sclerosis

Drugs & Therapeutics for Relapsing-Remitting Multiple Sclerosis

Sources:
5CenterWatch, 42NIH Clinical Center, 6ClinicalTrials, 61UMLS, 41NDF-RT
See all sources

Approved drugs:

Search CenterWatch for Relapsing-Remitting Multiple Sclerosis

Drug clinical trials:

Search ClinicalTrials for Relapsing-Remitting Multiple Sclerosis

Search NIH Clinical Center for Relapsing-Remitting Multiple Sclerosis

Search CenterWatch for Relapsing-Remitting Multiple Sclerosis

Inferred drug relations via UMLS61/NDF-RT41:

Genetic Tests for Relapsing-Remitting Multiple Sclerosis

Anatomical Context for Relapsing-Remitting Multiple Sclerosis

Sources:
33MalaCards
See all sources

MalaCards organs/tissues related to Relapsing-Remitting Multiple Sclerosis:

33
Spinal cord, Brain, Lung, Bone marrow, Whole blood, Cortex, Thyroid, Myeloid, Monocytes, T cells, B cells, Endothelial, Adrenal cortex, Pituitary

Animal Models for Relapsing-Remitting Multiple Sclerosis or affiliated genes

Sources:
28inGenious Targeting Laboratory
See all sources

Publications for Relapsing-Remitting Multiple Sclerosis

Sources:
51PubMed
See all sources

Articles related to Relapsing-Remitting Multiple Sclerosis:

(show top 50)    (show all 586)
idTitleAuthorsYear
1
Disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with daclizumab high-yield process in the SELECT study. (24022270)
2013
2
Reactivity to AQP4 epitopes in relapsing-remitting multiple sclerosis. (23673145)
2013
3
Efficacy and safety of BG-12 (dimethyl fumarate) and other disease-modifying therapies for the treatment of relapsing-remitting multiple sclerosis: a systematic review and mixed treatment comparison. (24195574)
2013
4
Lesion-to-ventricle distance and other risk factors for the persistence of newly formed black holes in relapsing-remitting multiple sclerosis. (23846352)
2013
5
Assessment of definitions of sustained disease progression in relapsing-remitting multiple sclerosis. (23555057)
2013
6
Health-related quality of life as an independent predictor of long-term disability for patients with relapsing-remitting multiple sclerosis. (23347258)
2013
7
Daclizumab for relapsing remitting multiple sclerosis. (24363032)
2013
8
Effect of daclizumab high-yield process in patients with highly active relapsing-remitting multiple sclerosis. (24375015)
2013
9
In active relapsing-remitting multiple sclerosis, effector T cell resistance to adaptive T(regs) involves IL-6-mediated signaling. (23363979)
2013
10
Treatments for relapsing-remitting multiple sclerosis: summarising current information by network meta-analysis. (22057838)
2012
11
Association between use of interferon beta and progression of disability in patients with relapsing-remitting multiple sclerosis. (22797642)
2012
12
A review of interferon use in patients with relapsing remitting multiple sclerosis in the Canterbury region, New Zealand: 2000-2006. (22382255)
2012
13
Can a physician predict the clinical response to first-line immunomodulatory treatment in relapsing-remitting multiple sclerosis? (23118540)
2012
14
Quantitative MRI and cerebrospinal fluid inflammatory mediators in Brazilian patients with relapsing-remitting multiple sclerosis before and after treatment with immunomodulators: a longitudinal study. (22472803)
2012
15
Cost-utility analysis of disease-modifying drugs in relapsing-remitting multiple sclerosis in Iran. (24250871)
2012
16
New and Emerging Disease-Modifying Therapies for Relapsing-Remitting Multiple Sclerosis: What is New and What is to Come. (23650470)
2012
17
Influence of histocompatibility genes on disease susceptibility and treatment response in patients with relapsing-remitting multiple sclerosis treated with interferon I^-1a. (21785677)
2011
18
Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial. (22047971)
2011
19
Mycophenolate mofetil in combination with interferon beta-1a in the treatment of relapsing-remitting multiple sclerosis: A preliminary study. (21448376)
2011
20
Efficacy and tolerability of natalizumab in relapsing-remitting multiple sclerosis patients: a post-marketing observational study. (20544247)
2011
21
Gender effects on intramuscular interferon beta-1a in relapsing-remitting multiple sclerosis: analysis of 1406 patients. (20965959)
2011
22
Impact of exposure to interferon beta-1a on outcomes in patients with relapsing-remitting multiple sclerosis: exploratory analyses from the PRISMS long-term follow-up study. (21339904)
2011
23
Effect of IFN-beta therapy on the frequency and function of CD4(+)CD25(+) regulatory T cells and Foxp3 gene expression in relapsing-remitting multiple sclerosis (RRMS): a preliminary study. (19932513)
2010
24
Oral laquinimod in patients with relapsing-remitting multiple sclerosis: 36-week double-blind active extension of the multi-centre, randomized, double-blind, parallel-group placebo-controlled study. (20834039)
2010
25
Health-related quality of life in relapsing remitting multiple sclerosis patients during treatment with glatiramer acetate: a prospective, observational, international, multi-centre study. (21078142)
2010
26
TI-relaxation time changes over five years in relapsing-remitting multiple sclerosis. (20086026)
2010
27
Failure of glatiramer acetate to modify the peripheral T cell repertoire of relapsing-remitting multiple sclerosis patients. (20116333)
2010
28
Boosting endogenous neuroprotection in multiple sclerosis: the ASsociation of Inosine and Interferon beta in relapsing- remitting Multiple Sclerosis (ASIIMS) trial. (20200198)
2010
29
Intramuscular interferon beta-1a therapy in patients with relapsing-remitting multiple sclerosis: a 15-year follow-up study. (20167591)
2010
30
Routine interferon-neutralising antibody testing in patients with relapsing-remitting multiple sclerosis. (21125049)
2010
31
Comparing the cost-effectiveness of disease-modifying drugs for the first-line treatment of relapsing-remitting multiple sclerosis. (19739877)
2009
32
Oral fumarate for relapsing-remitting multiple sclerosis. (18970966)
2008
33
Measuring adherence and persistence to disease-modifying agents among patients with relapsing remitting multiple sclerosis. (19019804)
2008
34
Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study. (18703004)
2008
35
B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. (18272891)
2008
36
Rituximab in relapsing-remitting multiple sclerosis. (18557177)
2008
37
Preliminary evidences of a NOS2A protective effect from relapsing-remitting multiple sclerosis. (17854833)
2008
38
Quality Assessment in Multiple Sclerosis Therapy (QUASIMS): a comparison of interferon beta therapies for relapsing-remitting multiple sclerosis. (17273808)
2007
39
Natalizumab: A new treatment for relapsing remitting multiple sclerosis. (18360634)
2007
40
Investigating the role of brain-derived neurotrophic factor in relapsing-remitting multiple sclerosis. (16740142)
2007
41
Interferon beta-1a therapy enhances CD4+ regulatory T-cell function: an ex vivo and in vitro longitudinal study in relapsing-remitting multiple sclerosis. (17157927)
2007
42
Ingested (oral) IFN-alpha represses TNF-alpha mRNA in relapsing-remitting multiple sclerosis. (16542137)
2006
43
Matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of matrix metalloproteinase (TIMP-1) in patients with relapsing-remitting multiple sclerosis treated with interferon beta. (16412833)
2006
44
IFN-beta treatment modulates the CD28/CTLA-4-mediated pathway for IL-2 production in patients with relapsing-remitting multiple sclerosis. (15584487)
2004
45
Long-Term Cost Effectiveness of Interferon-beta-1a in the Treatment of Relapsing-Remitting Multiple Sclerosis : An Econometric Model. (17535070)
2003
46
Differential release of beta-chemokines in serum and CSF of patients with relapsing-remitting multiple sclerosis. (11493224)
2001
47
Interferon beta1a treatment modulates TH1 expression in gammadelta + T cells from relapsing-remitting multiple sclerosis patients. (11403227)
2001
48
Effects of rIFN-beta-1b on serum circulating ICAM-1 in relapsing remitting multiple sclerosis and on the membrane-bound ICAM-1 expression on brain microvascular endothelial cells. (10871785)
2000
49
Recombinant interferon-beta-1a: a review of its therapeutic efficacy in relapsing-remitting multiple sclerosis. (18020616)
1998
50
Composite cerebrospinal fluid score in relapsing-remitting and secondary progressive multiple sclerosis. (9762656)
1998

Genetic Variations for Relapsing-Remitting Multiple Sclerosis

Expression for genes affiliated with Relapsing-Remitting Multiple Sclerosis

Sources:
1BioGPS, 15Gene Expression Omnibus DataSets
See all sources
Expression patterns in normal tissues for genes affiliated with Relapsing-Remitting Multiple Sclerosis

Search GEO for disease gene expression data for Relapsing-Remitting Multiple Sclerosis.

Pathways for genes affiliated with Relapsing-Remitting Multiple Sclerosis

Sources:
54Reactome, 12EMD Millipore, 30KEGG
See all sources

Compounds for genes affiliated with Relapsing-Remitting Multiple Sclerosis

Sources:
45Novoseek, 24HMDB, 50PharmGKB, 29IUPHAR, 11DrugBank
See all sources

Compounds related to Relapsing-Remitting Multiple Sclerosis according to GeneCards/GeneDecks:

(show all 24)
idCompoundScoreTop Affiliating Genes
1quinolinic acid45 2411.7HCRT, NTF3, NTF4
2pge24510.7PTAFR, IL23A
3tarc4510.7CXCL11, IFNB1, CCR7
4dexamethasone45 50 29 1113.7IFNB1, HCRT, CXCL11, NOG
5ccl345 2911.6CCR7, IFNB1, CXCL11
6ccl445 2911.6CXCL11, IFNB1, CCR7
7histamine45 29 2412.6AOC3, NTF4, NTF3, HCRT, PTAFR
8dopamine45 29 11 2413.6IFNB1, AOC3, NTF3, HCRT, NOG
9neopterin4510.6HLA-G, SAA4, IFNB1
10phosphatidylinositol4510.6KLRK1, CCR7, NTF4, NTF3, IL23A, PTAFR
11creatinine4510.5IFNB1, SAA4, HLA-G, AOC3
12rantes4510.5CCR7, IFNB1, CXCL11, PTAFR
13matrigel4510.5MMP19, NTF3, HLA-G, CCR7
14nitric oxide45 11 2412.5FOXP3, AOC3, NTF3, HCRT, IL23A, PTAFR
15ribonucleic acid4510.5HLA-G, NTF3, HCRT, NOG
16lipid4510.5CCR7, IFNB1, SAA4, HLA-G, AOC3, HCRT
17oxygen45 2411.5AOC3, HLA-G, KLRK1
18tyrosine4510.4CCR7, IFNB1, AOC3, NTF4, NTF3, HCRT
19norepinephrine45 11 2412.4CCR7, NTF3, HCRT
20p0034510.3AOC3, HLA-G, FOXP3
21calcium45 50 11 2413.3PTAFR, KLRK1, CCR7, IFNB1, SAA4, HLA-G
22retinoic acid45 2411.3KLRK1, IFNB1, NTF4, NTF3, NOG, PTAFR
23catecholamine4510.2HCRT, NTF3, AOC3
24cholesterol45 29 11 2412.9IFNB1, SAA4, HLA-G, AOC3, HCRT

GO Terms for genes affiliated with Relapsing-Remitting Multiple Sclerosis

Sources:
16Gene Ontology
See all sources

Cellular components related to Relapsing-Remitting Multiple Sclerosis according to GeneCards/GeneDecks:

idNameGO IDScoreTop Affiliating Genes
1extracellular regionGO:00557610.1NOG, MMP19, CXCL11, HCRT, IGHG3, NTF3

Biological processes related to Relapsing-Remitting Multiple Sclerosis according to GeneCards/GeneDecks:

(show all 8)
idNameGO IDScoreTop Affiliating Genes
1positive regulation of interleukin-12 productionGO:03273510.5IL23A, HLA-G, CCR7
2mechanoreceptor differentiationGO:04249010.5NTF3, NTF4
3negative regulation of interleukin-10 productionGO:03269310.4IL23A, FOXP3
4inflammatory responseGO:00695410.4CCR7, AOC3, CXCL11, IL23A, PTAFR
5elevation of cytosolic calcium ion concentrationGO:00720410.4CCR7, HCRT, CD52
6positive regulation of neutrophil chemotaxisGO:09002310.3IL23A, CCR7
7positive regulation of transcription from RNA polymerase II promoterGO:04594410.3NOG, IL23A, NTF3, FOXP3, IFNB1
8immune responseGO:00695510.0CCR7, IGHG3, CXCL11, PTAFR

Products for genes affiliated with Relapsing-Remitting Multiple Sclerosis

  • Antibodies
  • Proteins
  • Lysates
  • Antibodies

Sources for Relapsing-Remitting Multiple Sclerosis

3CDC
13ExPASy
14FMA
22GTR
23HGMD
24HMDB
25ICD10
26ICD10 via Orphanet
27ICD9CM
29IUPHAR
30KEGG
35MeSH
36MESH via Orphanet
37MGI
40NCIt
41NDF-RT
44NINDS
45Novoseek
47OMIM
48OMIM via Orphanet
51PubMed
52QIAGEN
58SNOMED-CT via Orphanet
61UMLS
62UMLS via Orphanet